Author pages are created from data sourced from our academic publisher partnerships and public sources.
Efficacy and safety of sunitinib in patients with advanced gastrointestinal stromal tumour after failure of imatinib: a randomised controlled trial
BACKGROUND No effective therapeutic options for patients with unresectable imatinib-resistant gastrointestinal stromal tumour are available. We did a randomised, double-blind, placebo-controlled,… Expand
Consensus meeting for the management of gastrointestinal stromal tumors. Report of the GIST Consensus Conference of 20-21 March 2004, under the auspices of ESMO.
- J. Blay, S. Bonvalot, +18 authors G. Demetri
- Annals of oncology : official journal of the…
- 1 April 2005
BACKGROUND The management of gastrointestinal stromal tumors (GIST) has evolved very rapidly in the last 4 years. The objectives of this international consensus meeting were to describe the optimal… Expand
Malignant peripheral nerve sheath tumors
The authors explored the prognostic factors and clinical outcomes of patients who had malignant peripheral nerve sheath tumors (MPNST) with and without neurofibromatosis type 1 (NF‐1).
Gastrointestinal stromal tumours: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up.
Gastrointestinal stromal tumours (GISTs) are rare tumours, with an estimated unadjusted incidence of around 1/100 000/ year . This only covers clinically relevant GISTs, since it is likely that a… Expand
Progression-free survival in gastrointestinal stromal tumours with high-dose imatinib: randomised trial
- J. Verweij, P. Casali, J. Zalcberg, A. Lecesne, the Australasian Gastrointestinal Trials Group
- The Lancet
- 25 September 2004
BACKGROUND Imatinib is approved worldwide for use in gastrointestinal stromal tumours (GIST). We aimed to assess dose dependency of response and progression-free survival with imatinib for metastatic… Expand
KIT mutations and dose selection for imatinib in patients with advanced gastrointestinal stromal tumours.
A recent randomized EORTC phase III trial, comparing two doses of imatinib in patients with advanced gastrointestinal stromal tumours (GISTs), reported dose dependency for progression-free survival.… Expand
Descriptive epidemiology of sarcomas in Europe: report from the RARECARE project.
Sarcomas are a heterogeneous group of malignant neoplasms arising from mesenchymal cells which encompass dozens of histological types and can occur in virtually any anatomic site. They form one of… Expand
Role of macrophage targeting in the antitumor activity of trabectedin.
There is widespread interest in macrophages as a therapeutic target in cancer. Here, we demonstrate that trabectedin, a recently approved chemotherapeutic agent, induces rapid apoptosis exclusively… Expand
Rhabdomyosarcoma in adults
The goal of the current study was to clarify treatment outcomes for adult patients with rhabdomyosarcoma (RMS). Published series have reported definitively worse results for adults with RMS compared… Expand
Synovial sarcoma: A retrospective analysis of 271 patients of all ages treated at a single institution
The optimal treatment strategy for synovial sarcoma (SS) is subject to debate, and different strategies have been used for pediatric and adult patients. The current retrospective analysis examined a… Expand